HC Wainwright Comments on Traws Pharma FY2030 Earnings

Traws Pharma, Inc. (NASDAQ:TRAW) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Traws Pharma in a research note issued to investors on Wednesday, May 20th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of $0.52 for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($2.72) per share.

Several other analysts have also recently issued reports on the company. LADENBURG THALM/SH SH upgraded Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. Weiss Ratings cut Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Traws Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Traws Pharma Trading Up 1.9%

Shares of NASDAQ TRAW opened at $1.62 on Thursday. The stock has a market cap of $16.46 million, a P/E ratio of -0.96 and a beta of 1.47. Traws Pharma has a 12-month low of $1.00 and a 12-month high of $3.27. The business’s fifty day simple moving average is $1.68 and its 200-day simple moving average is $1.83.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.39.

Insider Buying and Selling

In other Traws Pharma news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.67 per share, with a total value of $998,207.43. Following the completion of the acquisition, the insider directly owned 1,203,250 shares of the company’s stock, valued at $2,009,427.50. This represents a 98.71% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 14.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Traws Pharma

Large investors have recently bought and sold shares of the business. Two Sigma Investments LP grew its holdings in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the last quarter. State Street Corp purchased a new position in shares of Traws Pharma during the fourth quarter worth about $29,000. XTX Topco Ltd grew its holdings in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Traws Pharma during the fourth quarter worth about $56,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.